Milestone Pharmaceuticals, Inc. (MIST)

Milestone Pharmaceuticals' stock has been impacted by several key events over the past six months. The FDA approval and U.S. launch of CARDAMYST™ in late 2025 and early 2026 served as a positive catalyst. CARDAMYST™ became available on Express Scripts formularies in March 2026. The company reported its first revenue of $1.5 million from a licensing collaboration in its Q4 2025 financial results. The EMA accepted etripamil nasal spray for review. Analyst ratings were upgraded, with Raymond James initiating coverage with a "Strong Buy" rating. The stock price has fluctuated, with a 52-week low of $0.69 and a high of $3.06, and as of April 8, 2026, the share price was $1.78. Milestone Pharmaceuticals announced the RESET-PSVT registry, a Phase 4 observational study, in April 2026.

Information regarding the specific demand seasonality for Milestone Pharmaceuticals' products is limited. While one source indicates a "Seasonality Score: -10", another observation suggests a potential positive trend for the stock in April. Given that CARDAMYST™ treats acute PSVT episodes, it is less likely to have strong seasonal demand fluctuations.

Milestone Pharmaceuticals, Inc., a Canada-based biopharmaceutical company, focuses on developing and commercializing cardiovascular medicines. Operating in the Biotechnology & Medical Research sector, its primary product is CARDAMYST™ (etripamil) nasal spray, a rapid-onset calcium channel blocker for self-administration. CARDAMYST™ is FDA-approved for converting acute PSVT episodes to sinus rhythm in adults, and is being investigated for AFib-RVR and other cardiovascular indications.

Milestone Pharmaceuticals is headquartered in Montreal, Quebec, Canada, and its product, CARDAMYST™ nasal spray, is available in the United States. The company also has a U.S. subsidiary, Milestone Pharmaceuticals USA, Inc.

Milestone Pharmaceuticals' brand reputation has been significantly enhanced by the FDA approval and commercial launch of CARDAMYST™. This approval, the first new option in 30 years for PSVT patients, positions the company as an innovator. The EMA's acceptance of etripamil for review further boosts its reputation. Analyst upgrades reflect a positive perception of the company's potential. Although an initial FDA rejection in March 2025 caused a stock dip, the subsequent approval has led to a positive shift in reputation.

Milestone Pharmaceuticals has a diverse ownership structure, with approximately 16.54% to 22.14% held by institutional investors, 1.36% by insiders, and around 80.19% by public companies and individual investors. Major institutional owners include Propel Bio Management, LLC, Adage Capital Partners Gp, L.l.c., and RTW Investments, LP, among others.